Novorapid Penfill

Novorapid Penfill is used for blood sugar control in people with type 1 and type 2 diabetes mellitus. It is a fast-acting type of insulin that helps to lower blood sugar levels after meals and reduce the chances of developing serious complications of diabetes.

Novorapid Penfill is normally prescribed along with a long-acting type of insulin or other diabetes medicines. Your doctor or nurse will teach you the correct way of injecting it under the skin. It should be taken 15 minutes before a meal or within 20 minutes after starting a meal. Check your blood sugar levels regularly, keep track of your results and share them with your doctor. This is very important to work out the correct dose of the medicine for you.

Do not use this medicine when you have low blood sugar levels (hypoglycemia). Tell your doctor if you have ever had kidney, liver, or heart problems before starting treatment. Pregnant or breastfeeding women should also consult their doctor as the dose may need to be changed. Do not stop taking it unless your doctor tells you to. It is only part of a treatment program that should also include a healthy diet, regular exercise, and weight reduction as advised by your doctor.

The most common side effect of this medicine is low blood sugar levels (hypoglycemia). To prevent this, it is important to always inject the correct dose of medicine only, have regular meals, and monitor your blood sugar levels regularly. Drinking excessive alcohol can also lead to a fall in your blood sugar levels. Other side effects include allergies at the injection site like redness, swelling, or hard lumps (lipodystrophy). Some people gain weight while taking insulin.

• Diabetes

Diabetes
Novorapid Penfill is a modern, rapid-acting form of insulin that helps to control high blood glucose (sugar) levels. It replaces the insulin that is normally produced in the body. This helps the glucose get into your cells so your body can use it for energy. It begins to lower your blood glucose level within 10-20 minutes of injecting it and the effect can last for 3-5 hours. You will need to learn exactly how, where, and when to inject this medicine for it to be most effective.

Lowering blood glucose levels helps reduce the risk of getting any of the serious complications of diabetes such as kidney damage, eye damage, nerve problems, and loss of limbs. Taking this medicine regularly along with proper diet and exercise will help you live a normal, healthy life.

Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them

Common side effects of Novorapid

• Hypoglycemia (low blood glucose level)
• Auto-antibody formation
• Headache
• Nasopharyngitis (inflammation of the throat and nasal passages)
• Upper respiratory tract infection

Your doctor or nurse will guide you how to use this medicine.

Novorapid Penfill is fast-acting insulin. It starts working within 10-20 minutes after injection. It works like your body's natural insulin. Insulin facilitates reuptake of glucose in muscles and fat cells and also blocks the release of glucose from the liver.

• Novorapid Penfill helps to control blood sugar levels and avoid long-term complications.

• Take it 15 minutes before a meal or within 20 minutes after starting a meal.

• Hypoglycemia (low blood sugar level) is a common side effect. Monitor your blood sugar level regularly.

• Always carry some sugary food or fruit juice with you in case you experience hypoglycemia symptoms such as cold sweats, cool pale skin, tremors, weakness, and anxiety.

• Injection below the skin of the abdomen results in faster absorption than other injection sites.

• Injection sites must be rotated to prevent hard lumps from developing at one site.

• Opened vials/cartridges stay good at room temperature for up to 4 weeks, while unopened vials must be placed in the refrigerator (2°C–8°C).

• Do not use it if the preparation is no longer clear and colorless or if it contains particles.

Powers AC, D’Alessio D. Endocrine Pancreas and Pharmacotherapy of Diabetes Mellitus and Hypoglycemia. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. 12th ed. New York, New York: McGraw-Hill Medical; 2011. p. 1251.

Nolte MS. Pancreatic hormones and antidiabetic drugs. In: Katzung BG, Masters SB, Trevor AJ, editors. Basic and Clinical Pharmacology. 11th ed. New Delhi, India: Tata McGraw Hill Education Private Limited; 2009. pp. 733.

Briggs GG, Freeman RK, editors. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation. 10th ed. Philadelphia, PA: Wolters Kluwer Health; 2015. pp. 717-18.

Insulin aspart. Bagsvaerd, Denmark: Novo Nordisk A/S; 2000 [revised Mar. 2008]. [Accessed 12 Mar. 2019] (online) Available from:

Chaves RG, Lamounier JA. Breastfeeding and maternal medications. J Pediatr (Rio J). 2004;80(5 Suppl):S189-98. [Accessed 12 Mar. 2019] (online) Available from:

Insulin Aspart [Product monograph]. Ontario, Canada: Novo Nordisk Canada Inc.; 2021. [Accessed 08 Oct. 2021] (online) Available from:

Insulin Aspart [Summary of Product Characteristics]. Paris, France: Sanofi-Aventis Groupe; 2020. [Accessed 08 Oct. 2021] (online) Available from: